
Letter to the FSHD Community from Sarepta
26 March 2026 We welcome the announcement from Sarepta Therapeutics on early clinical data from its siRNA program targeting FSHD.
Stay connected with the latest developments in FSHD research and community progress. This is your trusted hub for updates on scientific breakthroughs, inspiring personal stories, and the work we’re doing globally to accelerate treatments and a cure for Facioscapulohumeral Muscular Dystrophy (FSHD).
By staying informed and engaged, you’re helping us raise awareness, support individuals and families impacted by FSHD, and drive real momentum toward lasting solutions.

26 March 2026 We welcome the announcement from Sarepta Therapeutics on early clinical data from its siRNA program targeting FSHD.

19 March 2026 Overnight, Roche has shared with the FSHD community that it will discontinue its Phase II MANOEUVRE trial

August 2025 FSHD Global Research Foundation recently visited the Murdoch Children’s Research Institute (MCRI) and The Royal Children’s Hospital to

On September 15th, the Sydney FSHD community gathered for an unforgettable evening of connection and discovery. Generously hosted by UBS,

Patients with a common type of muscular dystrophy a world-first AI powered disease progression model with ‘life-changing’ implications, using advanced

By Mitch Albert Boccia is a dynamic and inclusive Paralympic sport designed specifically for people with physical disabilities. It offers
We publish a monthly newsletter to keep the FSHD community informed, connected, and inspired. If there’s a story you’d like to tell, a question you’d like answered, or a topic you think we should explore, we’d love to hear from you.
Send an email to admin@fshdglobal.org.